To assess the safety of infusing AB-110, cord blood (CB) hematopoietic stem and progenitor cells (HSPCs) with engineered human umbilical vein endothelial cells.
A PHASE 1B, OPEN LABEL, MULTI-CENTER TRIAL OF AB-110 IN ADULTS WITH HEMATOLOGIC MALIGNANCIES UNDERGOING CORD BLOOD TRANSPLANTATION
I - Research Studies that focus on the safety of a drug. The goal is to determine the drug's most frequent and serious adverse events and, often, how the drug is broken down and excreted by the body. These studies usually involve a small number of participants.
University of Colorado Hospital
Jonathan Gutman, MD
Protocol Number: 17-2078
More information available at ClinicalTrials.gov: NCT03483324
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers